{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:32:58Z","timestamp":1793316778378,"version":"4.5.0"},"reference-count":116,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T00:00:00Z","timestamp":1679011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Basic to Translational Science"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jacbts.2023.03.017","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T17:44:21Z","timestamp":1686159861000},"page":"1245-1261","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"title":["Inflammasome Signaling, Thromboinflammation, and Venous\u00a0Thromboembolism"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6585-4870","authenticated-orcid":false,"given":"Nicola","family":"Potere","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Abbate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogendra","family":"Kanthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Carrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Toldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ettore","family":"Porreca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Di Nisio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jacbts.2023.03.017_bib1","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1161\/CIRCRESAHA.116.306853","article-title":"Cross talk pathways between coagulation and inflammation","volume":"118","author":"Foley","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.jacbts.2023.03.017_bib2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri3345","article-title":"Thrombosis as an intravascular effector of innate immunity","volume":"13","author":"Engelmann","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jacbts.2023.03.017_bib3","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41577-021-00536-9","article-title":"Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19","volume":"21","author":"Bonaventura","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jacbts.2023.03.017_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104299","article-title":"Interleukin-1 and the NLRP3 inflammasome in COVID-19: pathogenetic and therapeutic implications","volume":"85","author":"Potere","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jacbts.2023.03.017_bib5","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","article-title":"The NLRP3 inflammasome: molecular activation and regulation to therapeutics","volume":"19","author":"Swanson","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jacbts.2023.03.017_bib6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrcardio.2017.161","article-title":"The NLRP3 inflammasome in acute myocardial infarction","volume":"15","author":"Toldo","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacbts.2023.03.017_bib7","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1161\/CIRCRESAHA.120.315937","article-title":"Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease","author":"Abbate","year":"2020","journal-title":"Circ Res"},{"key":"10.1016\/j.jacbts.2023.03.017_bib8","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/FJC.0000000000000709","article-title":"Cell-specific roles of NLRP3 inflammasome in myocardial infarction","volume":"74","author":"Takahashi","year":"2019","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.jacbts.2023.03.017_bib9","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.immuni.2019.04.003","article-title":"Inflammasome activation triggers blood clotting and host death\u00a0through pyroptosis","volume":"50","author":"Wu","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.jacbts.2023.03.017_bib10","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.4049\/jimmunol.1202388","article-title":"Neutrophil extracellular trap\u2013associated protein activation of the NLRP3 inflammasome is enhanced in lupus macrophages","volume":"190","author":"Kahlenberg","year":"2013","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jacbts.2023.03.017_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2021.683803","article-title":"NLRP3 inflammasome assembly in neutrophils is supported by PAD4 and promotes NETosis under sterile conditions","volume":"12","author":"M\u00fcnzer","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jacbts.2023.03.017_bib12","doi-asserted-by":"crossref","first-page":"4763","DOI":"10.1073\/pnas.1620458114","article-title":"Activation of NLRP3 inflammasome complex potentiates venous thrombosis in response to hypoxia","volume":"114","author":"Gupta","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacbts.2023.03.017_bib13","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1182\/bloodadvances.2020003041","article-title":"Inflammasome activation promotes venous thrombosis through pyroptosis","volume":"5","author":"Zhang","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jacbts.2023.03.017_bib14","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/bloodadvances.2020003377","article-title":"Neutrophil extracellular traps and inflammasomes cooperatively promote venous thrombosis in mice","volume":"5","author":"Campos","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jacbts.2023.03.017_bib15","first-page":"2872","volume":"129","author":"Yadav","year":"2019","journal-title":"ENTPD-1 disrupts inflammasome IL-1\u03b2 \u2013 driven venous thrombosis. J Clin Invest"},{"key":"10.1016\/j.jacbts.2023.03.017_bib16","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/s41569-021-00552-1","article-title":"Interplay between inflammation and thrombosis in cardiovascular pathology","volume":"18","author":"Stark","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacbts.2023.03.017_bib17","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1016\/S0140-6736(16)30514-1","article-title":"Deep vein thrombosis and pulmonary embolism","volume":"388","author":"Di Nisio","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jacbts.2023.03.017_bib18","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nrcardio.2015.83","article-title":"Epidemiology of venous thromboembolism","volume":"12","author":"Heit","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacbts.2023.03.017_bib19","doi-asserted-by":"crossref","first-page":"l4363","DOI":"10.1136\/bmj.l4363","article-title":"Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis","volume":"366","author":"Khan","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jacbts.2023.03.017_bib20","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000000130","article-title":"The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association","volume":"130","author":"Kahn","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2023.03.017_bib21","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.critrevonc.2016.01.007","article-title":"Inflammation as a cause of venous thromboembolism","volume":"99","author":"Saghazadeh","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jacbts.2023.03.017_bib22","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1161\/CIRCRESAHA.121.318225","article-title":"Inflammation, infection and venous thromboembolism","author":"Colling","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.jacbts.2023.03.017_bib23","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1160\/TH03-03-0152","article-title":"Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures","volume":"90","author":"White","year":"2003","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacbts.2023.03.017_bib24","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/rth2.12065","article-title":"Acute infection as a trigger for incident venous thromboembolism: results from a population-based case-crossover study","volume":"2","author":"Grimnes","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jacbts.2023.03.017_bib25","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(06)68474-2","article-title":"Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting","volume":"367","author":"Smeeth","year":"2006","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jacbts.2023.03.017_bib26","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/annonc\/mdj068","article-title":"Risk factors for venous thromboembolic events in cancer patients","volume":"17","author":"Kr\u00f6ger","year":"2006","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.jacbts.2023.03.017_bib27","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1111\/jth.13369","article-title":"C-reactive protein, obesity, and the risk of arterial and venous thrombosis","volume":"14","author":"Horvei","year":"2016","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jacbts.2023.03.017_bib28","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jacc.2019.10.058","article-title":"Incident heart failure and long-term risk for venous thromboembolism","volume":"75","author":"Fanola","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacbts.2023.03.017_bib29","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1681\/ASN.2007030308","article-title":"Chronic kidney disease increases risk for venous thromboembolism","volume":"19","author":"Wattanakit","year":"2008","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.jacbts.2023.03.017_bib30","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0140-6736(11)61306-8","article-title":"Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden","volume":"379","author":"Z\u00f6ller","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jacbts.2023.03.017_bib31","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/CIRCRESAHA.115.306656","article-title":"From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection","volume":"118","author":"Ridker","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.jacbts.2023.03.017_bib32","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1093\/eurheartj\/ehaa1103","article-title":"C-reactive protein and clinical outcomes in patients with COVID-19","volume":"42","author":"Smilowitz","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacbts.2023.03.017_bib33","article-title":"Factors associated with risk of postdischarge thrombosis in patients with COVID-19","volume":"4(11):e2135397","author":"Li","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacbts.2023.03.017_bib34","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3324\/haematol.2017.186957","article-title":"C-reactive protein and risk of venous thromboembolism: results from a population-based case-crossover study","volume":"103","author":"Grimnes","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.jacbts.2023.03.017_bib35","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1161\/ATVBAHA.109.198473","article-title":"C-reactive protein and risk of venous thromboembolism in the general population","volume":"30","author":"Zacho","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacbts.2023.03.017_bib36","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s10654-017-0277-4","article-title":"Serum C-reactive protein increases the risk of venous thromboembolism: a prospective study and meta-analysis of published prospective evidence","volume":"32","author":"Kunutsor","year":"2017","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.jacbts.2023.03.017_bib37","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1067\/mva.2002.121746","article-title":"Inflammatory response in the acute phase of deep vein thrombosis","volume":"35","author":"Roumen-Klappe","year":"2002","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jacbts.2023.03.017_bib38","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1177\/1076029613494469","article-title":"The role of the nonspecific inflammatory markers in determining the anatomic extent of venous thromboembolism","volume":"21","author":"Bakirci","year":"2015","journal-title":"Clin Appl Thromb"},{"key":"10.1016\/j.jacbts.2023.03.017_bib39","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jvsv.2015.04.005","article-title":"Association between inflammation biomarkers, anatomic extent of deep venous thrombosis, and venous symptoms after deep venous thrombosis","volume":"3","author":"Rabinovich","year":"2015","journal-title":"J\u00a0Vasc Surg Venous Lymphat Disord"},{"key":"10.1016\/j.jacbts.2023.03.017_bib40","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/j.1538-7836.2009.03286.x","article-title":"Inflammation in deep vein thrombosis and the development of post-thrombotic syndrome: a prospective study","volume":"7","author":"Roumen-Klappe","year":"2009","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jacbts.2023.03.017_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12959-020-00253-8","article-title":"Predictors of long-term post-thrombotic syndrome following high proximal deep vein thrombosis: a cross-sectional study","volume":"19","author":"Engeseth","year":"2021","journal-title":"Thromb J"},{"key":"10.1016\/j.jacbts.2023.03.017_bib42","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1538-7836.2004.00689.x","article-title":"Activation of innate immunity in patients with venous thrombosis: the Leiden Thrombophilia Study","volume":"2","author":"Reitsma","year":"2004","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jacbts.2023.03.017_bib43","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.jvs.2004.07.004","article-title":"C-reactive protein and red cell aggregation correlate with late venous function after acute deep venous thrombosis","volume":"40","author":"Krieger","year":"2004","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jacbts.2023.03.017_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227150","article-title":"Increased inflammation and endothelial markers in patients with late severe post-thrombotic syndrome","volume":"15","author":"Bittar","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jacbts.2023.03.017_bib45","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1160\/TH08-08-0511","article-title":"Levels of inflammatory markers and the development of the post-thrombotic syndrome","volume":"101","author":"Shbaklo","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacbts.2023.03.017_bib46","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/jth.12814","article-title":"Inflammation markers and their trajectories after deep vein thrombosis in relation to risk of post-thrombotic syndrome","volume":"13","author":"Rabinovich","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jacbts.2023.03.017_bib47","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1111\/j.1538-7836.2012.04798.x","article-title":"Markers of coagulation, fibrinolysis and inflammation in relation to post-thrombotic syndrome","volume":"10","author":"Bouman","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jacbts.2023.03.017_bib48","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1055\/s-0037-1613858","article-title":"Recurrent venous thrombosis and markers of inflammation","volume":"83","author":"Van Aken","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacbts.2023.03.017_bib49","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/s41416-018-0269-5","article-title":"D-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis","volume":"119","author":"Jara-Palomares","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jacbts.2023.03.017_bib50","doi-asserted-by":"crossref","DOI":"10.1177\/10760296211013107","article-title":"Upregulation of inflammatory cytokines in pulmonary embolism using biochip-array profiling","author":"Bontekoe","year":"2021","journal-title":"Clin Appl Thromb"},{"key":"10.1016\/j.jacbts.2023.03.017_bib51","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2310\/JIM.0b013e31820017f2","article-title":"C-reactive protein in acute pulmonary embolism","volume":"59","author":"Abul","year":"2011","journal-title":"J\u00a0Investig Med"},{"key":"10.1016\/j.jacbts.2023.03.017_bib52","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/cvr\/cvab010","article-title":"NLRP3 inflammasome as a key driver of vascular disease","volume":"118","author":"Takahashi","year":"2022","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacbts.2023.03.017_bib53","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1128\/CMR.00046-08","article-title":"Pathogen recognition and inflammatory signaling in innate immune defenses","volume":"22","author":"Mogensen","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jacbts.2023.03.017_bib54","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nri.2016.58","article-title":"Inflammasomes: mechanism of assembly, regulation and signalling","volume":"16","author":"Broz","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jacbts.2023.03.017_bib55","doi-asserted-by":"crossref","first-page":"108053","DOI":"10.1016\/j.pharmthera.2021.108053","article-title":"Targeting the NLRP3 inflammasome in cardiovascular diseases","volume":"236","author":"Toldo","year":"2021","journal-title":"Pharmacol Ther"},{"issue":"suppl 1","key":"10.1016\/j.jacbts.2023.03.017_bib56","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/jth.12261","article-title":"Crossroads of coagulation and innate immunity: the case of deep vein thrombosis","volume":"11","author":"Schulz","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jacbts.2023.03.017_bib57","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1073\/pnas.96.5.2311","article-title":"Blood-borne tissue factor: another view of thrombosis","volume":"96","author":"Giesen","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacbts.2023.03.017_bib58","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1096\/fj.02-0574fje","article-title":"Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets","volume":"17","author":"M\u00fcller","year":"2003","journal-title":"FASEB J"},{"key":"10.1016\/j.jacbts.2023.03.017_bib59","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1084\/jem.20112322","article-title":"Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in\u00a0vivo","volume":"209","author":"von Br\u00fchl","year":"2012","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jacbts.2023.03.017_bib60","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1172\/JCI79329","article-title":"Caspase-1\u2013mediated pathway promotes generation of thromboinflammatory microparticles","volume":"125","author":"Rothmeier","year":"2015","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacbts.2023.03.017_bib61","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1182\/blood-2013-04-460139","article-title":"Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients","volume":"122","author":"Geddings","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jacbts.2023.03.017_bib62","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.4049\/jimmunol.1102048","article-title":"IL-1\u03b1 and IL-1\u03b2 recruit different myeloid cells and promote different stages of sterile inflammation","volume":"187","author":"Rider","year":"2011","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jacbts.2023.03.017_bib63","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1182\/blood-2012-06-437772","article-title":"Tissue factor\u2013positive neutrophils bind to injured endothelial wall and initiate thrombus formation","volume":"120","author":"Darbousset","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jacbts.2023.03.017_bib64","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1161\/ATVBAHA.119.312463","article-title":"Neutrophil extracellular traps: villains and targets in arterial, venous, and cancer-associated thrombosis","volume":"39","author":"Th\u00e5lin","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacbts.2023.03.017_bib65","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.bbrc.2016.12.161","article-title":"The NLRP3 inflammasome and bruton\u2019s tyrosine kinase in platelets co-regulate platelet activation, aggregation, and in\u00a0vitro thrombus formation","volume":"483","author":"Murthy","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jacbts.2023.03.017_bib66","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.cyto.2016.10.016","article-title":"Differential synthesis and release of IL-18 and IL-18 binding protein from human platelets and their implications for HIV infection","volume":"90","author":"Allam","year":"2017","journal-title":"Cytokine"},{"key":"10.1016\/j.jacbts.2023.03.017_bib67","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1182\/blood-2009-11-252643","article-title":"Platelet interleukin-1\u03b1 drives cerebrovascular inflammation","volume":"115","author":"Thornton","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jacbts.2023.03.017_bib68","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.bbrc.2018.11.125","article-title":"TLR4-dependent upregulation of the platelet NLRP3 inflammasome promotes platelet aggregation in a murine model of hindlimb ischemia","volume":"508","author":"Vogel","year":"2019","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"10.1016\/j.jacbts.2023.03.017_bib69","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1055\/s-0041-1731288","article-title":"Rapid release of interleukin-1\u03b2 from human platelets is independent of NLRP3 and caspase","volume":"122","author":"Pennings","year":"2022","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacbts.2023.03.017_bib70","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1161\/ATVBAHA.113.302700","article-title":"Interleukin 1 receptor 1 and interleukin 1\u03b2 regulate megakaryocyte maturation, platelet activation, and transcript profile during inflammation in mice and humans","volume":"34","author":"Beaulieu","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacbts.2023.03.017_bib71","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.3324\/haematol.2018.191700","article-title":"NLRP3 regulates platelet integrin \u03b1IIb\u03b23 outside-in signaling, hemostasis and arterial thrombosis","volume":"103","author":"Qiao","year":"2018","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.jacbts.2023.03.017_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107615","article-title":"Platelets fuel the inflammasome activation of innate immune cells","volume":"31","author":"Rolfes","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.jacbts.2023.03.017_bib73","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1182\/blood-2013-05-504449","article-title":"Platelets mediate increased endothelium permeability in dengue through NLRP3-inflammasome activation","volume":"122","author":"Hottz","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jacbts.2023.03.017_bib74","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s41419-020-02985-x","article-title":"NLRP3 inflammasome in endothelial dysfunction","volume":"11","author":"Bai","year":"2020","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jacbts.2023.03.017_bib75","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.4049\/jimmunol.2000217","article-title":"NLRP3 inflammasome activation in lung vascular endothelial cells contributes to intestinal ischemia\/reperfusion-induced acute lung injury","volume":"205","author":"Ito","year":"2020","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jacbts.2023.03.017_bib76","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1084\/jem.160.2.618","article-title":"Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells","volume":"160","author":"Bevilacqua","year":"1984","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jacbts.2023.03.017_bib77","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/jnc.13422","article-title":"IL-1alpha induces angiogenesis in brain endothelial cells in\u00a0vitro: implications for brain angiogenesis after acute injury","volume":"136","author":"Salmeron","year":"2016","journal-title":"J\u00a0Neurochem"},{"key":"10.1016\/j.jacbts.2023.03.017_bib78","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1073\/pnas.83.10.3460","article-title":"Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity","volume":"83","author":"Nawroth","year":"1986","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.jacbts.2023.03.017_bib79","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1161\/ATVBAHA.118.311150","article-title":"Neutrophil extracellular traps induce endothelial cell activation and tissue factor production through interleukin-1\u03b1 and cathepsin G","volume":"38","author":"Folco","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacbts.2023.03.017_bib80","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1479-5876-3-37","article-title":"Interleukin-1beta induced vascular permeability is dependent on induction of endothelial tissue factor (TF) activity","volume":"3","author":"Puhlmann","year":"2005","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.jacbts.2023.03.017_bib81","doi-asserted-by":"crossref","first-page":"10476","DOI":"10.1523\/JNEUROSCI.3357-07.2007","article-title":"Endothelial-specific knockdown of interleukin-1 (IL-1) type 1 receptor differentially alters CNS responses to IL-1 depending on its route of administration","volume":"27","author":"Ching","year":"2007","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.jacbts.2023.03.017_bib82","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1055\/s-0038-1646491","article-title":"The effect of interleukin-1 on venous endothelium--an ultrastructural study","volume":"66","author":"Merton","year":"1991","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacbts.2023.03.017_bib83","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1084\/jem.20011022","article-title":"Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages implications for atherogenesis","volume":"195","author":"Gerdes","year":"2002","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jacbts.2023.03.017_bib84","first-page":"883","article-title":"Correlation between the expression of IL-18 and deep venous thrombosis","volume":"42","author":"Li","year":"2018","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.jacbts.2023.03.017_bib85","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1161\/ATVBAHA.107.140384","article-title":"Haplotypes of IL1B, IL1RN, IL1R1, and IL1R2 and the risk of venous thrombosis","volume":"27","author":"Van Minkelen","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacbts.2023.03.017_bib86","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.21037\/jtd.2019.11.26","article-title":"Correlation study of venous thromboembolism with SAA, IL-1, and TNF-a levels and gene polymorphisms in Chinese population","volume":"11","author":"Abuduhalike","year":"2019","journal-title":"J\u00a0Thorac Dis"},{"key":"10.1016\/j.jacbts.2023.03.017_bib87","doi-asserted-by":"crossref","first-page":"e22345","DOI":"10.1002\/jcla.22345","article-title":"Association of interleukin-18 gene polymorphism and its protein expression with the lower extremity deep venous thrombosis in the Chinese han population: a case-control study","volume":"32","author":"Chen","year":"2018","journal-title":"J\u00a0Clin Lab Anal"},{"key":"10.1016\/j.jacbts.2023.03.017_bib88","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1002\/art.30588","article-title":"A\u00a0novel mutation of IL1RN in the deficiency of interleukin-1 receptor antagonist syndrome: description of two unrelated cases from Brazil","volume":"63","author":"Jesus","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jacbts.2023.03.017_bib89","doi-asserted-by":"crossref","first-page":"e94838","DOI":"10.1172\/jci.insight.94838","article-title":"Rilonacept maintains long-term inflammatory remission in patients with deficiency of the IL-1 receptor antagonist","volume":"2","author":"Garg","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.jacbts.2023.03.017_bib90","doi-asserted-by":"crossref","first-page":"e0132496","DOI":"10.1371\/journal.pone.0132496","article-title":"Increased levels of NF-dB-dependent markers in cancer-associated deep venous thrombosis","volume":"10","author":"Mala Ponte","year":"2015","journal-title":"Plops One"},{"key":"10.1016\/j.jacbts.2023.03.017_bib91","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1161\/ATVBAHA.119.312407","article-title":"Tuning the thromboinflammatory response to venous flow interruption by the ectonucleotidase CD39","volume":"39","author":"Anyanwu","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"suppl 1","key":"10.1016\/j.jacbts.2023.03.017_bib92","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1182\/blood-2022-160087","article-title":"Early dynamics of C-reactive protein predict risk of venous thromboembolism in patients with cancer treated with immune checkpoint inhibitors","volume":"140","author":"Moik","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jacbts.2023.03.017_bib93","doi-asserted-by":"crossref","first-page":"930797","DOI":"10.3389\/fcvm.2022.930797","article-title":"Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100\/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways","volume":"9","author":"Quagliariello","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jacbts.2023.03.017_bib94","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.semarthrit.2015.06.013","article-title":"Colchicine-Update on mechanisms of action and therapeutic uses","volume":"45","author":"Leung","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jacbts.2023.03.017_bib95","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/ni.2550","article-title":"Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome","volume":"14","author":"Misawa","year":"2013","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jacbts.2023.03.017_bib96","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1002\/jcb.24231","article-title":"The effect of colchicine on pyrin and pyrin interacting proteins","volume":"113","author":"Taskiran","year":"2012","journal-title":"J\u00a0Cell Biochem"},{"key":"10.1016\/j.jacbts.2023.03.017_bib97","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1182\/blood-2018-07-861237","article-title":"Neutrophil \u03b1-defensins promote thrombosis in\u00a0vivo by altering fibrin formation, structure, and stability","volume":"133","author":"Abu-Fanne","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.jacbts.2023.03.017_bib98","first-page":"A127","article-title":"Abstract 127: colchicine attenuates vein wall scarring in murine venous thrombosis: implications for limiting the post-thrombotic syndrome","volume":"37","author":"Qi","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacbts.2023.03.017_bib99","first-page":"742","article-title":"Inflammation in deep vein thrombosis: a therapeutic target?","volume":"24","author":"Borgel","year":"2019","journal-title":"Hematol (United Kingdom)"},{"key":"10.1016\/j.jacbts.2023.03.017_bib100","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1161\/CIRCRESAHA.120.317219","article-title":"Different DOACs control inflammation in cardiac ischemia-reperfusion differently","volume":"128","author":"Gadi","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.jacbts.2023.03.017_bib101","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1055\/s-0040-1701206","article-title":"Effects of rivaroxaban on biomarkers of coagulation and inflammation: a post hoc analysis of the X-VeRT trial","volume":"04","author":"Kirchhof","year":"2020","journal-title":"TH Open"},{"key":"10.1016\/j.jacbts.2023.03.017_bib102","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.thromres.2017.05.029","article-title":"Rivaroxaban versus warfarin in the prevention of post-thrombotic syndrome","volume":"157","author":"Jeraj","year":"2017","journal-title":"Thromb Res"},{"key":"10.1016\/j.jacbts.2023.03.017_bib103","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1160\/TH16-01-0041","article-title":"Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin\/vitamin K antagonists for acute deep-vein thrombosis: a post-hoc analysis","volume":"116","author":"Cheung","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacbts.2023.03.017_bib104","first-page":"133","volume":"45","author":"San Norberto","year":"2016","journal-title":"Effects of rosuvastatin as an adjuvant treatment for deep vein thrombosis"},{"key":"10.1016\/j.jacbts.2023.03.017_bib105","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa0900241","article-title":"A\u00a0randomized trial of rosuvastatin in the prevention of venous thromboembolism","volume":"360","author":"Glynn","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.jacbts.2023.03.017_bib106","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/cvr\/cvab078","article-title":"Rosuvastatin for the prevention of venous thromboembolism: a pooled analysis of the HOPE-3 and JUPITER randomized controlled trials","volume":"18","author":"Joseph","year":"2022","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacbts.2023.03.017_bib107","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/FJC.0000000000000931","article-title":"Phase 1B, randomized, double-blinded, dose escalation, single-center, repeat dose safety and pharmacodynamics study of the oral NLRP3 inhibitor dapansutrile in subjects with NYHA II-III systolic heart failure","volume":"77","author":"Wohlford","year":"2020","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.jacbts.2023.03.017_bib108","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S2665-9913(20)30065-5","article-title":"Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial","volume":"2","author":"Kl\u00fcck","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jacbts.2023.03.017_bib109","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low-dose colchicine for secondary prevention of cardiovascular disease","volume":"61","author":"Nidorf","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacbts.2023.03.017_bib110","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacbts.2023.03.017_bib111","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1161\/CIRCULATIONAHA.120.050560","article-title":"Colchicine attenuates inflammation beyond the inflammasome in chronic coronary artery disease: a LoDoCo2 proteomic substudy","volume":"142","author":"Opstal","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2023.03.017_bib112","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacbts.2023.03.017_bib113","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/eurheartj\/ehu272","article-title":"The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study","volume":"36","author":"Morton","year":"2015","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.jacbts.2023.03.017_bib114","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/ehjcvp\/pvab075","article-title":"Interleukin-1 blockade with anakinra and heart failure following ST-segment elevation myocardial infarction: results from a pooled analysis of the VCUART clinical trials","volume":"8","author":"Abbate","year":"2022","journal-title":"Eur Hear J - Cardiovasc Pharmacother"},{"key":"10.1016\/j.jacbts.2023.03.017_bib115","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1161\/CIRCULATIONAHA.112.122556","article-title":"Effects of interleukin-1\u03b2 inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen a phase IIb randomized, placebo-controlled trial","volume":"126","author":"Ridker","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2023.03.017_bib116","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N\u00a0Engl J Med"}],"container-title":["JACC: Basic to Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452302X23001250?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452302X23001250?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:26:48Z","timestamp":1762820808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452302X23001250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":116,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S2452302X23001250"],"URL":"https:\/\/doi.org\/10.1016\/j.jacbts.2023.03.017","relation":{},"ISSN":["2452-302X"],"issn-type":[{"value":"2452-302X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inflammasome Signaling, Thromboinflammation, and Venous\u00a0Thromboembolism","name":"articletitle","label":"Article Title"},{"value":"JACC: Basic to Translational Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacbts.2023.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}